|
|
Volumn 55, Issue 6, 2015, Pages 647-656
|
|
Canagliflozin use in patients with renal impairment - Utility of quantitative clinical pharmacology analyses in dose optimization
a
|
|
Author keywords
canagliflozin; diabetes; regulatory; renal impairment; SGLT2
|
|
Indexed keywords
CANAGLIFLOZIN;
GLUCOSE;
HEMOGLOBIN A1C;
SODIUM GLUCOSE COTRANSPORTER 2;
ANTIDIABETIC AGENT;
BIOLOGICAL MARKER;
GLUCOSE BLOOD LEVEL;
ARTICLE;
CLINICAL DECISION MAKING;
CONTROLLED CLINICAL TRIAL (TOPIC);
DIABETIC PATIENT;
DIET;
DRUG EFFICACY;
DRUG SAFETY;
ELECTROLYTE DISTURBANCE;
EXERCISE;
FOOD AND DRUG ADMINISTRATION;
GLOMERULUS FILTRATION RATE;
GLYCEMIC CONTROL;
HUMAN;
KIDNEY DISEASE;
KIDNEY TUBULE ABSORPTION;
NEPHROTOXICITY;
NON INSULIN DEPENDENT DIABETES MELLITUS;
OPTIMAL DRUG DOSE;
PHASE 3 CLINICAL TRIAL (TOPIC);
QUANTITATIVE ANALYSIS;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
RISK BENEFIT ANALYSIS;
SIDE EFFECT;
URINARY EXCRETION;
ADULT;
AGONISTS;
BLOOD;
CLINICAL PHARMACOLOGY;
DIABETES MELLITUS, TYPE 2;
DOSE RESPONSE;
DRUG EFFECTS;
GLUCOSE BLOOD LEVEL;
KIDNEY;
KIDNEY FAILURE;
METABOLISM;
PATHOPHYSIOLOGY;
PROCEDURES;
ADULT;
BIOMARKERS;
BLOOD GLUCOSE;
CANAGLIFLOZIN;
DIABETES MELLITUS, TYPE 2;
DOSE-RESPONSE RELATIONSHIP, DRUG;
GLOMERULAR FILTRATION RATE;
HUMANS;
HYPOGLYCEMIC AGENTS;
KIDNEY;
PHARMACOLOGY, CLINICAL;
RENAL INSUFFICIENCY;
SODIUM-GLUCOSE TRANSPORTER 2;
|
|
EID: 84928891886
PISSN: 00912700
EISSN: 15524604
Source Type: Journal
DOI: 10.1002/jcph.466 Document Type: Article |
|
Times cited : (6)
|
|
References (7)
|
